The Role of Newer Antiarrhythmic Drugs in the Management of Patients with Ventricular Arrhythmias

Cain, Michael E.
July 1988
Angiology;Jul1988 Part 2, Vol. 39 Issue 7, p668
Academic Journal
The purpose of this review is to discuss the role of mexiletine, to-cainide, flecainide, and amiodarone in the treatment of patients with symptomatic ventricular ectopy or sustained ventricular tachycardia (VT) and fibrillation (VF). The pharmacologic properties, electrophysio-logic effects, clinical efficacy, adverse reactions, and costs of these new agents are compared with those of procainamide, quinidine, and disopyramide. With the exception of more convenient dosing intervals, these new agents do not afford novel or advantageous pharmacologic properties. The incidences and severity of adverse reactions are similar to those reported with conventional antiar-rhythmic drugs. Results of clinical studies demonstrate that these newer drugs are comparable to procainamide, quinidine, and disopyramide in suppressing ventricular ectopy. Accordingly, the choice of an antiar-rhythmic agent for patients with symptomatic ventricular ectopy can be based on the side-effect profile. The propensity for developing certain adverse effects can be defined if patients are subgrouped by age and left ventricular function. The adverse effects of amiodarone preclude its use in patients manifesting only ventricular ectopy. Treatment of patients with sustained VT/VF is more complex. Mexiletine and tocainide are generally not effective. The efficacy of flecainide is similar to that of procainamide, quinidine, and disopyramide. The negative inotropic effects of flecainide and disopyramide preclude their use in patients with severe ventricular dysfunction. Amiodarone is the most effective of these drugs for preventing recurrences of sustained VT/VF. Its use should, however, be restricted to patients refractory or intolerant to other antiarrhythmic drugs.


Related Articles

  • Evaluation of Quinidine Short and Long-Acting in Control of Arrhythmias. Coodley, Eugene; Pugash, Neil; Toppo, Frank // Angiology;Sep1984, Vol. 35 Issue 9, p581 

    Twenty-one patients with arrhythmias responsive to quinidine were studied both with regard to consistency of response as determined by repeat Holter Monitoring and in half of these patients a comparison of short and long-acting quinidine was made. Holter Monitoring demonstrated greater than 60%...

  • Pharmacologic Reversion of Persistent Atrial Fibrillation with Amiodarone Predicts Long-Term Sinus Rhythm Maintenance. Galperín, Jorge; Elizari, Marcelo V.; Chiale, Pablo A.; Molina, Remberto Torres; Ledesma, Raul; Scapín, Angel O.; x00c1;zquez# Blanco, Manuel V&; Bonato, Richardo; Lago, Manuel // Journal of Cardiovascular Pharmacology & Therapeutics;Sep2003, Vol. 8 Issue 3, p179 

    The article analyzes the role of different variables that determine long-term sinus rhythm maintenance in patients with persistent atrial fibrillation who are treated with amiodarone. It has been recognized that different factors influence long-term sinus rhythm preservation after the conversion...

  • Arrhythmia Control by Selective Lengthening of Cardiac Repolarization: Role of N--Acetylprocainamide, Active Metabolite of Procainamide. Singh, Bramah N.; Feld, Gregory; Nademanee, Koonlawee // Angiology;Dec1986 Part 2, Vol. 37 Issue 12, p930 

    In recent years, data has become available to support the concept that a selective lengthening of the cardiac action potential (a Class III antiarrhythmic action) by whatever mechanism with an attendant increase in the effective refractory period constitutes a distinct antiarrhythmic mechanism....

  • Amiodarone-Induced Pulmonary Toxicity: Predisposing Factors, Clinical Symptoms and Treatment. Jessurun, G.A.J.; Boersma, W.G.; Crijns, H.J.G.M. // Drug Safety;May1998, Vol. 18 Issue 5, p339 

    Amiodarone is frequently used for the treatment of cardiac arrhythmias. Although the therapeutic efficacy of amiodarone has been established, its use is limited by its safety profile. Amiodarone-induced pulmonary toxicity is one of the most life-threatening complications of this therapy. It is a...

  • EVALUATION OF A NEW QUINIDINE COMPOUND: A COMPARATIVE STUDY. Pote, Harry H. // Angiology;Jul1961, Vol. 12 Issue 7, p320 

    Twenty-five patients with various cardiac arrhythmias were treated with a new quinidine salt, quinidine polygalacturonate. The usual daily dosage was one 275-mg tablet. Duration of therapy averaged 133 days In 50 per cent of the patients, quinidine polygalacturonate provided more satisfactory...

  • Electrical Storm in Patients with Implantable Cardioverter-Defibrillators. Emkanjoo, Zahra; Alihasani, Narges; Alizadeh, Abolfath; Tayyebi, Mohammad; Bonakdar, Hamid; Barakpour, Hamid; Sadr-Ameli, Mohammad Ali // Texas Heart Institute Journal;2009, Vol. 36 Issue 6, p563 

    The aim of this retrospective study was to determine the prevalence and predictors of electrical storm in 227 patients who had received implantable cardioverter-defibrillators (ICDs) and had been monitored for 31.7 ± 15.6 months. Of these, 174 (77%) were men. The mean age was 55.8 ± 15.5...

  • Tolvaptan Administration Does Not Affect Steady State Amiodarone Concentrations in Patients With Cardiac Arrhythmias. Shoaf, Susan Elizabeth; Elizari, Marcelo Vítor; Zhao Wang; Sekar, Kumara; Grinfeld, Liliana Rosa; Barbagelata, N. Alejandro; Lerman, Jorge; Bramer, Steven Lee; Trongé, Jorge; Orlandi, Cesare // Journal of Cardiovascular Pharmacology & Therapeutics;Sep2005, Vol. 10 Issue 3, p165 

    Cites a study which found that tolvaptan, a nonpeptide selective vasopressin receptor antagonist, does not affect steady state amiodarone concentrations in patients with cardiac arrhythmias. Extent of the pharmacokinetic interaction between tolvaptan and amiodarone, a antiarrhythmic drug;...

  • Amiodarone and Warfarin Interaction. Miller, Karl E. // American Family Physician;4/15/2002, Vol. 65 Issue 8, p1669 

    Reports on a study by C.A. Sanoski and colleagues on the interaction between amiodarone, an effective medication used in the treatment of life-threatening ventricular arrhythmias, and warfarin in patients receiving this combination of drugs for at least one day. Analysis of the study and its...

  • What you must know about amiodarone. Dulak, Sally Beattie // Healthcare Traveler;May2005, Vol. 12 Issue 11, p56 

    Focuses on amiodarone, an antiarrhythmics which can prevent and treat ventricular and supraventricular dysrhythmias. Year the drug was introduced; Most common dysrhythmia; Reason amiodarone is referred to primarily as a Class III antiarrhythmic.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics